Rhythmia Medical secures nearly $2.7 million in new equity funding to assist development of its heart-mapping device.

Rhythmia Medical Inc. raised nearly $2.7 million in a third-round equity sale to a group of 14 investors, according to new securities documents.
Burlington, Mass.-based Rhythmia, founded in 2004 by two Israeli entrepreneurs, is developing medical devices able to quickly map the electrical activity of the heart and pinpoint catheter ablation procedures.
The new funding round was disclosed in registration documents filed March 17 with the Securities & Exchange Commission. Previous funding rounds, including a $7 million, Series B package led three years ago by Boston-based Norwich Ventures, have provided Rhythmia Medical with nearly $12 million.
The company last year also received a pair of Small Business Innovation Research grants from the National Institutes of Health. Participants in the latest funding round were not disclosed.
Becton, Dickinson and Company's profits drop 10 percent during the third quarter on a $34...
Medtronic Inc. launches a global, randomized clinical trial of spinal cord stimulation as a treatment...
Baxter, Carefusion and Becton Dickinson among nine companies told by federal regulators to study...
Palomar Medical Technologies Inc. second quarter losses increases 600 percent due to heavy spending...
Chelmsford, Mass-based Zoll Medical Corp. records another strong quarter based on increased sales in...